基于对异丙基甲苯和二甲基双胍的对称双核钌(Ⅱ)配合物的合成及其体外抗癌活性  

Symmetrical Diruthenium(Ⅱ)Complex Based on 1-Isopropyl-4-methylbenzene and Dimethylbiguanide:Synthesis and Anticancer Activity in Vitro

作　　者：余群英 YU Qun-Ying(School of Pharmacy and Life Science,Jiujiang University,Jiujiang,Jiangxi 332000,China)

机构地区：[1]九江学院药学与生命科学学院,九江332000

出　　处：《无机化学学报》2021年第5期899-904,共6页Chinese Journal of Inorganic Chemistry

基　　金：江西省教育厅科学技术基金(No.GJJ180907);江西省卫生健康委科技计划项目(No.202131075)资助。

摘　　要：在碱性水溶液中合成了一种对称双核桥联配合物(NH_(4))_(2)[Ru(Cym)(L)]_(2)Cl_(2)·4H_(2)O(1)(Cym=对异丙基甲苯,H_(2)L=1,1-二甲基双胍)。采用红外光谱、核磁共振谱和X射线单晶衍射进行了结构表征,结晶水数目由热重分析法得出。采用MTT法测定了其对4种人癌细胞系HepG-2、A549、Hela、MCF-7的细胞毒性,以临床用药顺铂为对照,结果表明该配合物对HepG-2(肝细胞癌,HCC)的作用与顺铂相当。A novel symmetrical dinuclear bridging complex(NH_(4))_(2)[Ru(Cym)(L)]2Cl_(2)·4H_(2)O(1)(Cym=pcymene=1-isopropyl-4-methylbenzene,H,L=1,1-dimethylbiguanide)was obtained by treatment of the precursor[Ru(Cym)Cl_(2)]_(2)with metformin hydrochloride.In aqueous base solution,deprotonation of the proligand(1,1-dimethylbiguanide)occured and the corresponding neutral ruthenium complex 1 was obtained.The structure of complex 1 has been established by FT-IR and NMR spectroscopy and single-crystal X-ray diffraction analysis.The number of crystal water was obtained by thermogravimetric analysis.The inhibition of cell proliferation activity against four human cancer cell lines(HepG-2,A549,Hela,MCF-7)of complex 1 relative to cisplatin was measured by MTT method in vitro.Notably,the novel complex displayed comparable potency toward HepG-2(hepatocellular carcinoma,HCC)compared to cisplatin.CCDC:2058702.

关 键 词：钌配合物 晶体结构 抗癌活性 顺铂 

分 类 号：O614.821[理学—无机化学]